RBC Capital analyst Alistair Campbell lowered the firm’s price target on Genmab (GMAB) to DKK 2,300 from DKK 2,400 and keeps an Outperform ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the ...

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, ...

Truist analyst Asthika Goonewardene lowered the firm’s price target on Genmab (GMAB) to $45 from $50 but keeps a Buy rating on the shares.

Danish cancer specialist Genmab’s stock took a hit after US healthcare giant Johnson & Johnson opted not to license its ...

Company Announcement <li /> Johnson & Johnson has decided that it will not exercise its option to receive a ...

Genmab A/S posted the largest decline among large stocks during the session, falling 8.3%, followed by Novo Nordisk A/S shares, which declined 8.1%. Shares of Torm PLC A declined 7.1%.

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

The latest biotech to emerge from the Flagship Pioneering incubator – Lila Sciences – has emerged with $200 million in seed ...